Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed Mahmood, Michael G. Fradley, Justine V. Cohen, et al.
Journal of the American College of Cardiology (2018) Vol. 71, Iss. 16, pp. 1755-1764
Open Access | Times Cited: 1236

Showing 1-25 of 1236 citing articles:

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Circulation (2022) Vol. 145, Iss. 18
Open Access | Times Cited: 3058
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins, Sofiya Latifyan, Gerasimos P. Sykiotis, et al.
Nature Reviews Clinical Oncology (2019) Vol. 16, Iss. 9, pp. 563-580
Open Access | Times Cited: 1722
Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation
Vanessa M. Ferreira, Jeanette Schulz‐Menger, Godtfred Holmvang, et al.
Journal of the American College of Cardiology (2018) Vol. 72, Iss. 24, pp. 3158-3176
Open Access | Times Cited: 1572
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal (2022) Vol. 43, Iss. 41, pp. 4229-4361
Open Access | Times Cited: 1556
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 17, pp. e263-e421
Open Access | Times Cited: 1516
A review of cancer immunotherapy toxicity
Lucy Boyce Kennedy, April K.S. Salama
CA A Cancer Journal for Clinicians (2020) Vol. 70, Iss. 2, pp. 86-104
Open Access | Times Cited: 1100
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos‐Casals, Julie R. Brahmer, Margaret K. Callahan, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 1012
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Joe‐Elie Salem, Ali Manouchehri, Melissa Moey, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 12, pp. 1579-1589
Open Access | Times Cited: 964
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Giuseppe Curigliano, Daniel J. Lenihan, Michael G. Fradley, et al.
Annals of Oncology (2020) Vol. 31, Iss. 2, pp. 171-190
Open Access | Times Cited: 807
Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease
Dominic P. Del Re, Dulguun Amgalan, Andreas Linkermann, et al.
Physiological Reviews (2019) Vol. 99, Iss. 4, pp. 1765-1817
Open Access | Times Cited: 743
Immune-checkpoint inhibitors: long-term implications of toxicity
Douglas B. Johnson, Caroline A. Nebhan, Javid J. Moslehi, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 4, pp. 254-267
Open Access | Times Cited: 650
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
John B.A.G. Haanen, Michel Obéid, Lavinia Spain, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1217-1238
Open Access | Times Cited: 608
Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy
Enrico Ammirati, Maria Frigerio, Eric Adler, et al.
Circulation Heart Failure (2020) Vol. 13, Iss. 11
Open Access | Times Cited: 556
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002435-e002435
Open Access | Times Cited: 553
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology Society
Alexander R. Lyon, Susan Dent, Susannah Stanway, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 11, pp. 1945-1960
Open Access | Times Cited: 539
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, et al.
Journal of the National Comprehensive Cancer Network (2019) Vol. 17, Iss. 3, pp. 255-289
Open Access | Times Cited: 515
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Joerg Herrmann
Nature Reviews Cardiology (2020) Vol. 17, Iss. 8, pp. 474-502
Open Access | Times Cited: 514
Immune checkpoint inhibitors and cardiovascular toxicity
Alexander R. Lyon, Nadia Yousaf, Nicolò Matteo Luca Battisti, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 9, pp. e447-e458
Closed Access | Times Cited: 494
Recognition and Initial Management of Fulminant Myocarditis
Robb D. Kociol, Leslie T. Cooper, James C. Fang, et al.
Circulation (2020) Vol. 141, Iss. 6
Open Access | Times Cited: 489
Cardiovascular toxicities associated with immune checkpoint inhibitors
Jiun‐Ruey Hu, Roberta Florido, Evan J. Lipson, et al.
Cardiovascular Research (2019) Vol. 115, Iss. 5, pp. 854-868
Open Access | Times Cited: 412
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, et al.
Journal of the National Comprehensive Cancer Network (2020) Vol. 18, Iss. 3, pp. 230-241
Open Access | Times Cited: 405
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque
Zsófia D. Drobni, Raza M. Alvi, Jana Taron, et al.
Circulation (2020) Vol. 142, Iss. 24, pp. 2299-2311
Open Access | Times Cited: 401
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
Joerg Herrmann, Daniel J. Lenihan, Saro H. Armenian, et al.
European Heart Journal (2021) Vol. 43, Iss. 4, pp. 280-299
Open Access | Times Cited: 393
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
Nicolas L. Palaskas, Juan Lopez‐Mattei, Jean Bernard Durand, et al.
Journal of the American Heart Association (2020) Vol. 9, Iss. 2
Open Access | Times Cited: 380
Myocarditis in the Setting of Cancer Therapeutics
Marc P. Bonaca, Benjamin A. Olenchock, Joe-Élie Salem, et al.
Circulation (2019) Vol. 140, Iss. 1, pp. 80-91
Open Access | Times Cited: 354
Page 1 - Next Page

Scroll to top